Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity.
dc.contributor.author | Becker, Matthias | |
dc.contributor.author | Strengert, Monika | |
dc.contributor.author | Junker, Daniel | |
dc.contributor.author | Kaiser, Philipp D | |
dc.contributor.author | Kerrinnes, Tobias | |
dc.contributor.author | Traenkle, Bjoern | |
dc.contributor.author | Dinter, Heiko | |
dc.contributor.author | Häring, Julia | |
dc.contributor.author | Ghozzi, Stéphane | |
dc.contributor.author | Zeck, Anne | |
dc.contributor.author | Weise, Frank | |
dc.contributor.author | Peter, Andreas | |
dc.contributor.author | Hörber, Sebastian | |
dc.contributor.author | Fink, Simon | |
dc.contributor.author | Ruoff, Felix | |
dc.contributor.author | Dulovic, Alex | |
dc.contributor.author | Bakchoul, Tamam | |
dc.contributor.author | Baillot, Armin | |
dc.contributor.author | Lohse, Stefan | |
dc.contributor.author | Cornberg, Markus | |
dc.contributor.author | Illig, Thomas | |
dc.contributor.author | Gottlieb, Jens | |
dc.contributor.author | Smola, Sigrun | |
dc.contributor.author | Karch, André | |
dc.contributor.author | Berger, Klaus | |
dc.contributor.author | Rammensee, Hans-Georg | |
dc.contributor.author | Schenke-Layland, Katja | |
dc.contributor.author | Nelde, Annika | |
dc.contributor.author | Märklin, Melanie | |
dc.contributor.author | Heitmann, Jonas S | |
dc.contributor.author | Walz, Juliane S | |
dc.contributor.author | Templin, Markus | |
dc.contributor.author | Joos, Thomas O | |
dc.contributor.author | Rothbauer, Ulrich | |
dc.contributor.author | Krause, Gérard | |
dc.contributor.author | Schneiderhan-Marra, Nicole | |
dc.date.accessioned | 2021-03-25T15:21:07Z | |
dc.date.available | 2021-03-25T15:21:07Z | |
dc.date.issued | 2021-02-19 | |
dc.identifier.citation | Nat Commun. 2021 Mar 11;12(1):1577. doi: 10.1038/s41467-021-21609-2. | en_US |
dc.identifier.pmid | 33608538 | |
dc.identifier.doi | 10.1038/s41467-021-20973-3 | |
dc.identifier.uri | http://hdl.handle.net/10033/622797 | |
dc.description.abstract | The humoral immune response to SARS-CoV-2 is a benchmark for immunity and detailed analysis is required to understand the manifestation and progression of COVID-19, monitor seroconversion within the general population, and support vaccine development. The majority of currently available commercial serological assays only quantify the SARS-CoV-2 antibody response against individual antigens, limiting our understanding of the immune response. To overcome this, we have developed a multiplex immunoassay (MultiCoV-Ab) including spike and nucleocapsid proteins of SARS-CoV-2 and the endemic human coronaviruses. Compared to three broadly used commercial in vitro diagnostic tests, our MultiCoV-Ab achieves a higher sensitivity and specificity when analyzing a well-characterized sample set of SARS-CoV-2 infected and uninfected individuals. We find a high response against endemic coronaviruses in our sample set, but no consistent cross-reactive IgG response patterns against SARS-CoV-2. Here we show a robust, high-content-enabled, antigen-saving multiplex assay suited to both monitoring vaccination studies and facilitating epidemiologic screenings for humoral immunity towards pandemic and endemic coronaviruses. | en_US |
dc.language.iso | en | en_US |
dc.publisher | NPG | en_US |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/ 101003480 | en_US |
dc.rights | openAccess | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. | en_US |
dc.type | Article | en_US |
dc.identifier.eissn | 2041-1723 | |
dc.contributor.department | HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany. | en_US |
dc.identifier.journal | Nature communications | en_US |
dc.source.volume | 12 | |
dc.source.issue | 1 | |
dc.source.beginpage | 1152 | |
dc.source.endpage | ||
refterms.dateFOA | 2021-03-25T15:21:08Z | |
dc.source.journaltitle | Nature communications | |
dc.source.country | England |